Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Durvalumab (MEDI4736) in Hypermutated Metastatic Castration-Resistant Prostate Cancer

NCT02966587 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT02966587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02966587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Durvalumab (MEDI4736) in Hypermutated Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Withdrawn
Start date
May 15, 2018
Completion date
May 15, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration levels of testosterone, hormone-resistant prostate cancer, microsatellite instability